** Morningstar says it is upbeat on Australia's Telix Pharmaceuticals after co reported FY24 revenue ahead of its own and brokerage's forecasts

** "Telix is broadly tracking our expectations and we leave our constant-currency forecasts broadly unchanged," says brokerage

** Morningstar raises fair value estimate on stock by 6% to A$18, largely on stronger U.S. dollar

** Seven of eight analysts rate the stock "buy" or higher, one "hold"; their median PT is A$23.80 – LSEG data

** Stock has gained 1.5% YTD, as of last close

(Reporting by Rajasik Mukherjee in Bengaluru)

((Rajasik.Mukherjee@thomsonreuters.com;))